Program
fosfomycin sodium
Also written as “ZTI-01”, “ZTI-01 100 mg/kg” and “ZTI-01 75 mg/kg”.
Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma · Pyelonephritis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nabriva Therapeutics | 31 open or running | phase 3since Apr 13, 2016 | Apr 13, 2016 | none ahead |
| Meitheal Pharmaceuticals | 11 open or running | phase 4since May 8, 2026 | May 8, 2026 | Sep 2027phase 4 · NCT07618299 |
Also a collaborator on its studies: medpace-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 13, 2016First study: phase 3 study in Urinary Tract Infection SymptomaticNew to Nabriva TherapeuticsNabriva Therapeutics · NCT02753946 · 465 enrolled · United States, Belarus, Bulgaria and more
- May 8, 2018Phase 1 study in Cardiac Repolarization in Healthy SubjectsNabriva Therapeutics · NCT03709927 · 41 enrolled · United States
- Oct 10, 2018Phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNabriva Therapeutics · NCT03709914 · 21 planned · United States
- May 8, 2026Meitheal Pharmaceuticals's first study: phase 4 study in Healthy Lactating WomenNew to Meitheal PharmaceuticalsMeitheal Pharmaceuticals · NCT07618299 · 24 planned · South Africa
Ahead
- Sep 2027Primary completion: phase 4 study in Healthy Lactating WomenMeitheal Pharmaceuticals · NCT07618299
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor”ChEMBL 37, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07618299Healthy Lactating Women · South Africa | 4 | Recruiting | Meitheal Pharmaceuticals | Sep 2027 | 24 |
| NCT03709914Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States | 1 | Recruiting | Nabriva Therapeutics | Dec 31, 2025 | 21 |
| NCT03709927Cardiac Repolarization in Healthy Subjects · United States | 1 | Completed | Nabriva Therapeutics | Apr 12, 2018 | 41 |
| NCT02753946Urinary Tract Infection Symptomatic · United States, Belarus, Bulgaria and more | 3 | Completed | Nabriva Therapeutics | Jan 12, 2017 | 465 |
How it is read
Names in the registry
- “ZTI-01”, 3 entries
- “ZTI-01 100 mg/kg”, 1 entry
- “ZTI-01 75 mg/kg”, 1 entry
Conditions, from the studies’ own filings
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 study
- Pyelonephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.